Who is sponsoring NCT00790010?

NCT00790010 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT00790010?

Interventions in NCT00790010: Bevacizumab Plus Ipilimumab Cohort 1, Bevacizumab Plus Ipilimumab Cohort 2, Bevacizumab Plus Ipilimumab Cohort 3, Bevacizumab Plus Ipilimumab Cohort 4.

Is NCT00790010 still recruiting?

NCT00790010 is currently completed. Last updated 11 May 2023.

Last reviewed 2023-05-11 · How we verify

NCT00790010

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Completed Phase 1 Last updated 11 May 2023

What this trial tests

Phase 1 trial testing Bevacizumab Plus Ipilimumab Cohort 1 in Melanoma in 46 participants. Completed in 22 June 2018.

Timeline

26 February 2009

Primary endpoint
22 June 2018

22 June 2018

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	26 February 2009
Primary completion	22 June 2018
Estimated completion	22 June 2018
Sites	3 locations across United States

Drugs / interventions tested

Bevacizumab Plus Ipilimumab Cohort 1 — full drug profile →
Bevacizumab Plus Ipilimumab Cohort 2
Bevacizumab Plus Ipilimumab Cohort 3
Bevacizumab Plus Ipilimumab Cohort 4

Conditions studied

Melanoma — all drugs for Melanoma →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to determine the safety of using the study drugs bevacizumab and ipilimumab together, and the doses in combination which can be given to people safely. This study also seeks to investigate whether using both study drugs lengthens the amount of time before the participants melanoma worsens.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Combining immunotherapy and targeted therapies in cancer treatment.
Vanneman M, Dranoff G. · · 2012 · cited 1134× · PMID 22437869 · DOI 10.1038/nrc3237
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
Yi M, Jiao D, Qin S, Chu Q, et al · · 2019 · cited 487× · PMID 30925919 · DOI 10.1186/s12943-019-0974-6
Melanoma treatment in review.
Domingues B, Lopes JM, Soares P, Pópulo H. · · 2018 · cited 432× · PMID 29922629 · DOI 10.2147/itt.s134842
PD-1 as a potential target in cancer therapy.
McDermott DF, Atkins MB. · · 2013 · cited 309× · PMID 24403232 · DOI 10.1002/cam4.106
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, et al · · 2017 · cited 291× · PMID 28522460 · DOI 10.1158/2326-6066.cir-16-0329
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Lopes-Coelho F, Martins F, Pereira SA, Serpa J. · · 2021 · cited 254× · PMID 33916438 · DOI 10.3390/ijms22073765
Control of the immune response by pro-angiogenic factors.
Voron T, Marcheteau E, Pernot S, Colussi O, et al · · 2014 · cited 252× · PMID 24765614 · DOI 10.3389/fonc.2014.00070

Verify or expand the search:

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00790010 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 11 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00790010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing